Close Bookmark and Share This Page

Save to Browser Favorites / Bookmarks

Ask backflip blinklist BlogBookmark Bloglines BlogMarks Blogsvine BuddyMarks BUMPzee! CiteULike Connotea del.icio.us

Digg diigo DotNetKicks DropJack dzone Facebook Fark Faves Friendsite folkd.com Furl Google

Jamespot Jeqq Kaboodle kirtsy linkaGoGo LinkedIn Ma.gnolia Mister Wong Mixx MySpace Netvouz Newsvine

oneview OnlyWire PlugIM Propeller Reddit Segnalo Shoutwire Simpy Slashdot Surphace Sphinn Spurl

Squidoo StumbleUpon Technorati ThisNext Twitter Webride Windows Live Yahoo!

Email This to a Friend

  Link HTML: 

 Permalink: 

 If you like this then please subscribe to the RSS Feed.

Powered by Bookmarkify™

More »

View the full VVUS chart at Wikinvest

Stock Alert for VIVUS Inc. (VVUS)

VIVUS Inc. (VVUS) is a pharmaceutical company focused on the development and commercialization of therapeutic products. The Company’s product pipeline includes three late-stage clinical products, each addressing specific components of the obesity, diabetes and sexual health markets. One of these investigational products, Qnexa, is in phase III clinical trials for obesity and in phase II clinical trials for diabetes. The Company’s late-stage investigational product pipeline includes Qnexa for treating obesity, for which two of the phase III studies are in process and one phase III study has been completed; Qnexa for treating diabetes, for which a one-year phase II study has been completed; Avanafil, which is being developed for the treatment of erectile dysfunction, for which phase III studies are in process; and Luramist (Testosterone MDTS), which is being developed to treat hypoactive sexual desire disorder in women, for which a phase II study has been completed

Regards,

Don